PBM Transparency Requirements: What Payers Need to Know
PBM transparency reform has fundamentally changed what plan sponsors and health plans are legally required to understand, document, and demonstrate about their pharmacy benefit financials, although specific obligations vary by plan structure, applicable federal requirements, and state law. Many organizations are still working to close the gap between what disclosure rules demand and what their current data infrastructure can actually deliver. AscellaOne helps payers and plan sponsors build the operational visibility needed to make transparency requirements actionable, connecting pharmacy benefit data, financial workflows, and specialty pharmacy expertise within a single modular platform designed to support greater accountability across the full scope of pharmacy spend.
Why PBM Transparency Is Now a Strategic Imperative
Pharmacy benefit transparency has shifted from a compliance checkbox to a core operational concern for health plans, self-insured employers, and plan sponsors. Federal and state-level PBM reform legislation enacted in recent years has changed what payers are legally required to know about how their pharmacy benefits are priced, managed, and reported. And yet, many organizations are still operating with limited visibility into the financial flows that run through their pharmacy benefit contracts. That gap can create significant financial and compliance risk, particularly as transparency requirements continue to expand and evolve.
In 2026, plan sponsors and health plans face a more complex and demanding transparency environment, with requirements that can vary based on plan structure, applicable federal rules, and state law. The Department of Labor’s October 2026 final rule adds specific compensation disclosure requirements for PBMs and certain affiliated service providers working with large, self-insured ERISA group health plans. The rule is effective January 4, 2027, and applies to plan years beginning on or after July 1, 2027. Understanding what transparency requirements exist, what they demand operationally, and where organizations commonly fall short is the starting point for building a pharmacy benefit program that is both compliant and financially defensible.
What PBM Transparency Reform Actually Requires
PBM transparency reform, at both the federal and state level, targets the informational asymmetry that has long existed between pharmacy benefit managers and the plan sponsors who contract with them. Historically, PBMs controlled most of the data underlying a pharmacy benefit relationship, including drug pricing, rebate flows, spread amounts, network margins, and formulary decisions, without being required to share that data in usable, auditable format.
Reform legislation has moved to change that. The October 2026 Department of Labor final rule requires covered PBMs and certain affiliated brokerage and consulting service providers to disclose specified compensation information to fiduciaries of qualifying large, self-insured ERISA group health plans. This includes:
- Rebates and other payments received from drug manufacturers
- Compensation received when the amount a plan pays for a prescription exceeds the amount reimbursed to the dispensing pharmacy
- Payments recouped from pharmacies in connection with prescriptions dispensed to plan participants
- Other applicable direct and indirect compensation information required under the rule
These disclosures are intended to help plan fiduciaries evaluate the reasonableness of PBM compensation and the arrangements under which services are provided. The rule also provides plan fiduciaries with the ability to audit the accuracy of the required disclosures.
Separate federal requirements address broader prescription drug spending reporting and the pass-through of rebates, fees, and other remuneration. These provisions under the Consolidated Appropriations Act of 2026 generally apply to plan years beginning on or after August 3, 2028. They should not be confused with the earlier effective and applicability dates of the DOL’s October 2026 final rule.
State-level laws have added further requirements in many jurisdictions, covering PBM licensure, fiduciary duty, and mandatory pass-through of manufacturer rebates in certain program types. The cumulative effect is that plan sponsors now have both the legal standing and, increasingly, the regulatory authority to demand this information from their PBM partners, subject to the requirements applicable to their plan and jurisdiction.
The Operational Reality of Transparency Compliance
Knowing what disclosures are required is one thing. Being able to operationalize that information is another. Many health plans and plan sponsors are discovering that their current data infrastructure cannot actually absorb, reconcile, or audit the disclosures their PBMs are producing. Reports arrive in inconsistent formats. Rebate reconciliation data is delivered months after the corresponding claims period. Spread amounts are buried within aggregate financial summaries that obscure per-claim economics.
This is not a minor administrative friction. When plan sponsors cannot verify what they are paying for, they cannot evaluate whether their pharmacy benefit contract is performing as intended. Fiduciaries for self-insured plans, including plan administrators and benefits committees, have a legal obligation to act prudently with plan assets. If the data required to demonstrate prudent decision-making is inaccessible or unusable, that creates real compliance exposure.
Key Transparency Considerations for Health Plans and Plan Sponsors
Health plans administering pharmacy benefits for employer groups or government programs face a distinct set of transparency obligations compared to self-insured employers. Their obligations depend on the plan arrangement, their role in administering benefits, and the federal and state requirements that apply. The October DOL final rule specifically addresses disclosures by covered PBMs and affiliated service providers to fiduciaries of qualifying large, self-insured ERISA group health plans; it does not establish a blanket downstream disclosure obligation for every health plan.
For health plans specifically, the considerations worth prioritizing include:
- Ensuring PBM contracts include specific, enforceable audit rights and data access provisions, not just broad language about transparency
- Mapping every rebate stream, including volume-based discounts, administrative fees, and data licensing arrangements, to understand the full scope of total manufacturer remuneration
- Evaluating whether the plan’s formulary decisions can be documented as clinically and financially rational, independently of manufacturer financial relationships
- Confirming that reporting timelines in PBM contracts align with the regulatory disclosure deadlines now codified in applicable law
- Assessing whether the plan’s current reporting capabilities allow it to fulfill its own downstream disclosure obligations to plan sponsors where such obligations apply
Common Challenges Organizations Face
The most persistent challenge is data fragmentation. Pharmacy benefit data, medical claims data, specialty pharmacy data, and rebate accounting data typically live in separate systems managed by separate vendors. When a plan sponsor or health plan tries to produce a complete picture of pharmacy benefit economics, it often finds that the pieces do not fit together cleanly. Definitions differ across data sources. Timing conventions vary. And the PBM’s preferred reporting format does not always align with the format the plan sponsor needs for its own financial reporting or compliance submissions.
A second common challenge is contractual ambiguity. PBM contracts often include transparency language that sounds robust on its surface but contains carve-outs, definitional limitations, or proprietary data protections that limit what the plan sponsor can actually access. Organizations that have not recently reviewed their PBM contracts through a transparency-focused lens are frequently surprised by how narrow their actual disclosure rights actually turn out to be.
Third, there is the capacity problem. Even when good data is available, many plan sponsors and health plans lack internal expertise to interpret it, benchmark it, or use it to negotiate more favorable contract terms. Transparency is only as valuable as the organization’s ability to act on what the data reveals.
How Transparency Reform Is Reshaping PBM Contracting
In 2026, the effects of PBM transparency reform are showing up directly in how contracts are written and how negotiations proceed. Plan sponsors with sophisticated pharmacy benefit programs are increasingly demanding pass-through pricing models that eliminate spread, guaranteed net cost arrangements that tie PBM compensation to disclosed financials, and independent audit rights that provide meaningful access to the information needed to verify PBM disclosures. For plans covered by the DOL final rule, fiduciaries will have the right to audit the accuracy of the disclosures required under that rule. Broader audit rights, including access to claims pricing, rebate calculations, and other contract performance information, should be addressed through applicable contract provisions and other relevant legal requirements.
Health plans are also revisiting their administrative services agreements with PBMs to ensure that their own regulatory obligations are reflected in the contractual protections they hold. The shift is meaningful: where PBM contracts were once largely PBM-drafted and PBM-favoring, the transparency reform environment is giving well-prepared plan sponsors and health plans a clearer framework for demanding greater accountability.
This is also changing the competitive dynamics among PBMs. Transparent, pass-through PBMs that have built their model around fully disclosed financials are attracting more attention from plan sponsors who previously defaulted to legacy PBM relationships. That competition is healthy for the market, even if it introduces its own evaluation complexity for buyers who now must assess multiple PBM models side by side.
Building Internal Readiness for a Transparent Pharmacy Benefit Model
Organizations that want to move from passive recipients of PBM disclosures to active managers of pharmacy benefit economics need to build internal readiness across three areas. First, data infrastructure: the ability to receive, store, and reconcile pharmacy benefit data in a format that supports financial audit and compliance reporting. Second, contract governance: a formal process for reviewing PBM contracts against current transparency requirements, identifying gaps, and renegotiating those contracts where necessary. Third, analytical capacity: whether through internal staff, third-party consultants, or technology-enabled platforms, the ability to translate transparency data into actionable decisions about formulary strategy, network design, and PBM contract performance.
Organizations that treat transparency requirements as a compliance burden will find themselves perpetually reactive. Organizations that treat them as an operational discipline will find themselves in a much stronger position to manage pharmacy benefit costs and demonstrate their fiduciary responsibility to plan stakeholders.
What the Regulatory Landscape Looks Like
The regulatory environment governing PBM transparency continues to evolve. Federal agencies have issued additional guidance clarifying the scope of disclosure obligations for group health plans and their pharmacy benefit arrangements. In October 2026, the Department of Labor finalized a rule requiring covered PBMs and certain affiliated brokerage and consulting service providers to disclose specified compensation information to fiduciaries of qualifying large, self-insured ERISA group health plans. The rule is effective January 4, 2027, and applies to plan years beginning on or after July 1, 2027.
The final rule builds on amendments to ERISA’s service-provider disclosure provisions under the Consolidated Appropriations Act of 2026. Separate provisions under that legislation establish additional prescription drug spending reporting and rebate, fee, and other remuneration pass-through requirements, which generally apply to plan years beginning on or after August 3, 2028.
Several states have enacted or strengthened PBM reform laws that apply to fully insured products and, in some cases, self-insured plans operating within state jurisdiction. The direction is consistent: greater mandatory disclosure, stronger audit rights, and greater regulatory scrutiny of financial arrangements between PBMs and drug manufacturers.
Plan sponsors and health plans should not assume that existing PBM contracts, even recently renewed ones, fully reflect the current regulatory framework. A contract review cadence that accounts for ongoing legislative and regulatory changes is now a practical necessity, not merely an optional best practice.
How AscellaOne Supports Transparency-Driven Pharmacy Benefit Management
Payers and plan sponsors navigating PBM transparency requirements need more than a compliance checklist. They need pharmacy benefit infrastructure that surfaces the right data, connects financial and clinical workflows, and gives their teams the visibility and analytical capability to act on what they are seeing. That is where AscellaHealth’s AscellaOne platform is built to help.
AscellaOne is a modular pharmacy benefits enablement platform that integrates pharmacy access, financial optimization, specialty pharmacy expertise, and marketplace access into a single operating model. Rather than requiring health plans or plan sponsors to build that infrastructure from the ground up, AscellaOne provides the connective layer that brings fragmented pharmacy benefit data, services, and workflows into a more transparent and flexible structure, giving organizations greater visibility, control, and flexibility over their pharmacy benefit operations.
Specialty pharmacy is a particular area where transparency challenges concentrate. High-cost specialty drugs represent a disproportionate share of pharmacy benefit spend, and the financial arrangements governing specialty pharmacy access, including limited distribution networks, specialty rebate stacks, and site-of-care economics, are among the least transparent in the benefit landscape. AscellaHealth’s deep specialty pharmacy expertise means that clients working within AscellaOne have access to both the data infrastructure and the clinical and operational knowledge needed to manage specialty spend with greater accountability.
If your organization is building a more transparent, accountable pharmacy benefit program and looking for a platform that supports that work without requiring you to replace or rebuild your existing PBM relationships from scratch, explore what AscellaOne can add to your pharmacy benefit model. One Modular Platform. Total Pharmacy Benefits Control.
Frequently Asked Questions About PBM Transparency Reform
What is PBM transparency reform and why does it matter for plan sponsors?
PBM transparency reform refers to federal and state legislation requiring pharmacy benefit managers to disclose financial arrangements, including drug pricing, rebate flows, and spread pricing, to the plan sponsors and health plans they serve. The specific disclosures, covered parties, and implementation dates vary by law and plan type. The October 2026 DOL final rule, for example, establishes compensation disclosure requirements for covered PBMs and affiliated service providers working with qualifying large, self-insured ERISA group health plans. It matters because plan sponsors have fiduciary obligations to manage plan assets prudently, and that obligation requires access to accurate, auditable pharmacy benefit financial data to support informed oversight and decision-making.
What is spread pricing in pharmacy benefits, and is it still legal?
Spread pricing is the practice of a PBM charging a health plan a higher amount for a prescription than it actually pays the dispensing pharmacy, retaining the difference as revenue that may not be separately disclosed. Transparency reforms in multiple states have restricted or banned spread pricing in Medicaid managed care programs, and the October 2026 DOL final rule requires covered PBMs to disclose specified compensation associated with situations in which the amount paid by the plan exceeds the amount reimbursed to the pharmacy. This disclosure requirement applies to qualifying large, self-insured ERISA group health plans under the rule; it is not a blanket federal prohibition on spread pricing across all commercial markets. Spread pricing in commercial markets remains subject to ongoing regulatory scrutiny in 2026.
Are self-insured employers subject to PBM transparency requirements?
Self-insured employer-sponsored health plans are subject to federal transparency requirements under ERISA and the Consolidated Appropriations Act, including requirements governing certain service-provider disclosures and prescription drug spending reports. The October 2026 DOL final rule establishes specific PBM compensation disclosure requirements for qualifying large, self-insured ERISA group health plans. It is effective January 4, 2027, and applies to plan years beginning on or after July 1, 2027. Separate prescription drug spending reporting and rebate, fee, and other remuneration pass-through provisions under the 2026 legislation generally apply to plan years beginning on or after August 3, 2028. Plan fiduciaries must have sufficient information to evaluate the reasonableness of service-provider compensation and fulfill their fiduciary duties. State PBM laws may also apply depending on the plan’s structure and the state in which it operates.
What data should a plan sponsor be receiving from their PBM under current transparency rules?
The information a plan sponsor should receive depends on the applicable federal and state requirements, the plan’s structure, and its PBM contract. Under the October 2026 DOL final rule, covered PBMs must disclose specified compensation information to fiduciaries of qualifying large, self-insured ERISA group health plans, including manufacturer rebates and other payments, certain compensation associated with the difference between plan payments and pharmacy reimbursement, and pharmacy recoupments. Separate prescription drug spending reporting requirements under the 2026 legislation will apply on a later timeline. Plan sponsors should review their contracts and applicable requirements to determine the disclosures, reporting format, and timing that apply to their arrangements.
What is a pass-through pricing model in pharmacy benefits?
A pass-through pricing model is a PBM contract structure in which the plan sponsor pays the actual ingredient cost, dispensing fee, and rebate amounts as discrete, disclosed line items, with PBM compensation charged as a transparent administrative fee. Pass-through models can eliminate spread pricing and make the full economics of the pharmacy benefit visible to the plan sponsor.
How does PBM transparency reform affect specialty pharmacy management?
PBM transparency reform has particular implications for specialty pharmacy because specialty drugs involve complex financial arrangements, including limited distribution network agreements, manufacturer rebate tiers, and site-of-care differentials, that have historically been opaque. Where specialty pharmacy arrangements fall within the scope of applicable PBM disclosure requirements, the required compensation information can help plan fiduciaries evaluate those arrangements. The specific disclosures depend on the plan, the service provider, and the applicable federal or state requirements. Transparency requirements that apply to the broader pharmacy benefit also apply to specialty pharmacy arrangements to the extent those arrangements are covered by the relevant requirements, giving plan sponsors additional tools to evaluate whether their specialty drug spend is being managed in the plan’s best financial interest.
What audit rights should a health plan or plan sponsor have in their PBM contract?
Under the October 2026 DOL final rule, fiduciaries of qualifying large, self-insured ERISA group health plans have the right to audit the accuracy of the disclosures required under the rule. This is not an unrestricted right to audit every aspect of PBM claims pricing, rebate calculations, or network payment rates. Health plans and plan sponsors should also seek contractual audit rights that allow them to verify claims pricing, rebate calculations, spread amounts, and network payment rates using their own auditors or third-party consultants. Contracts that condition audit rights on PBM agreement to the scope or timing of an audit may provide weaker protection than clearly defined, enforceable audit provisions.
Can a health plan fulfill its downstream disclosure obligations if its PBM contract lacks adequate transparency provisions?
Whether a health plan has downstream disclosure obligations depends on its role, the structure of the plan arrangement, and the federal or state requirements that apply. The October 2026 DOL final rule specifically requires covered PBMs and certain affiliated service providers to make compensation disclosures to fiduciaries of qualifying large, self-insured ERISA group health plans; it does not create a universal downstream disclosure obligation for every health plan. If a health plan has applicable disclosure obligations but its PBM contract does not give it access to the underlying financial data it needs, the health plan may be unable to fulfill those obligations, which creates regulatory exposure depending on the circumstances and applicable law.
What should organizations do if their current PBM contract does not meet 2026 transparency requirements?
Organizations should first identify which federal and state transparency requirements apply to their plan and when those requirements take effect. For plans covered by the October 2026 DOL final rule, the rule is effective January 4, 2027, and applies to plan years beginning on or after July 1, 2027. Organizations should initiate a formal contract review, identify specific gaps against applicable federal and state requirements, and prioritize renegotiation of audit rights, disclosure timelines, and spread pricing provisions at the next contract renewal opportunity or, where exposure is significant, through a mid-term amendment process.
How is PBM transparency reform changing PBM market competition?
PBM transparency reform is increasing competitive pressure on legacy PBMs by giving plan sponsors clearer criteria for evaluating PBM performance and more specific contractual tools to demand accountability. Transparent, pass-through PBMs have gained market attention as the reform environment has made the cost of financial opacity more visible to buyers, and independent PBMs that can demonstrate transparent, straightforward financial models are finding a more receptive audience among plan sponsors who previously defaulted to incumbent relationships.
About AscellaHealth
Healthcare today is more complex than ever—especially when it comes to therapies for people living with rare and chronic conditions. These high-cost, high-impact treatments account for only a small fraction of prescriptions, but they make up the largest and fastest-growing share of total drug spend. As a result, balancing affordability and quality of care remains a significant challenge.
We’re here to change that.
Because at AscellaHealth, we believe that all patients in need should have the ability to access life-changing therapies.
Our Core Beliefs
At AscellaHealth, patients are not just part of the process—they’re why we do what we do. Every solution we build and every partnership we form is designed with the patient in mind.
Patients First, Always.
Balancing Cost and Care.
Better Stakeholder Outcomes.
